Erlotinib-related Severe Hair Loss with Severe Exanthematous Drug Eruption: A Case Report
10.0000/kjd.2018.56.2.139
- Author:
Jeong Nan KANG
1
;
Do Hyeong KIM
;
So Hee PARK
;
Jung Eun SEOL
;
Hyojin KIM
Author Information
1. Department of Dermatology, Busan Paik Hospital, College of Medicine, Inje University, Busan, Korea. derma09@hanmail.net
- Publication Type:Case Report
- Keywords:
Alopecia;
Drug-related adverse reactions;
Erlotinib
- MeSH:
Alopecia;
Arm;
Drug Eruptions;
Eosinophils;
Epidermis;
Erlotinib Hydrochloride;
Exocytosis;
Female;
Hair;
Humans;
Hypersensitivity;
Lung Neoplasms;
Middle Aged;
Neutrophils;
Receptor, Epidermal Growth Factor;
Scalp;
Skin
- From:Korean Journal of Dermatology
2018;56(2):139-142
- CountryRepublic of Korea
- Language:English
-
Abstract:
Erlotinib inhibits the epidermal growth factor receptor and is used in patients with various cancers. However, it can affect the epidermis and hair because the receptor is expressed in normal skin cells. A 54-year-old woman with metastatic non-small-cell lung cancer presented with erythematous patches over her entire body and severe hair shedding 2 weeks after starting erlotinib. Histopathological examinations showed lymphocytic exocytosis; perivascular infiltration of lymphohistiocytes and eosinophils in the right arm; and marked infiltration of eosinophils, neutrophils, and lymphohistiocytes in the scalp. Erlotinib discontinuation improved hair loss and skin lesions. Hair loss has been reported in 5% of patients taking erlotinib. Our case was unusual in that there was complete baldness, and to our knowledge, no report of complete hair loss and exanthematous drug eruption after erlotinib treatment has been previously reported. Here, we report a case of severe hair loss with concurrent exanthematous drug eruption that may have been linked to erlotinib hypersensitivity.
